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2015 is a very remarkable year for the European Association for
the Study of the Liver (EASL): we enter our 50th year, which
we will celebrate at the International Liver Conference (ILC) in
April in Vienna; at the same time, the Journal of Hepatology,
EASL’s ﬂagship journal, will celebrate its 30th anniversary, as it
experiences a tremendous increase in popularity. EASL was
founded as a small organization of highly motivated and dedi-
cated researchers, with a genuine interest in liver disease. Since
then, EASL has experienced signiﬁcant growth, particularly over
the last 10 years, driven in part by important structural changes
within the organization but also fuelled by an unprecedented
number of successful drug developments for a series of liver dis-
eases. The biggest success stories amongst these are the control
of hepatitis B and the development of a cure for hepatitis C, which
has the potential to eradicate chronic hepatitis C worldwide. This
rapid growth has transformed EASL from a small scientiﬁc soci-
ety, focused primarily on Europe, into a large multifaceted orga-
nization with a major focus on education, research, and public
policy in liver disease and related topics, increasingly focused
upon globally.
In 2014, EASL was pleased to organize the ILC in London, which
ended up being the biggest ILC so far with over 10,800 attendees
and the most spectacular scientiﬁc program in terms of game-
changing drug development ever. A little bit less obvious to the
average observer was the shift in the geographic distribution of
delegates at ILC: 4 out of the 10 largest nations represented at
ILC were from outside Europe, including 3 of the 4 BRIC countries.
There are several reasons for this, related to big societal changes
occurring both in Europe and around the world: Europe is experi-
encing a long-term economic downturn, which has triggered des-
ocialization within countries and has led to desolidarization, a
widening gap between population strata, and organizational
changes with the result that health services are increasingly being
run by economists, who tend to regard them more as a business
than a universal right any more. At the same time globally we
see new economic superpowers becoming more health and envi-
ronmentally conscious and starting to invest heavily in research
and education to transform formally low-production cost-driven
economies into knowledge-driven economies. A third importantJournal of Hepatology 20
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ing to changes in the relationship between professional medical
associations (PMOs) and the pharmaceutical industry. While no
one can predict what the future will bring, the nature and source
of funding, on which PMOs have relied for their growth is
changing.
When combined, all of these changes could be seen as massive
challenges for PMOs like EASL. However, EASL still embodies the
pioneering spirit that led to its creation and growth; we will not
rest on our laurels, no matter how bright the situation might
appear in 2014.
EASL is dedicated to growth through innovation as exempli-
ﬁed by the young, dynamic governing board, which is enthusias-
tically embracing these challenges and using them as a catalyst
for future growth. Big efforts have been made over the last
18 months by EASL to transcend these challenges and surpass
expectations.
An important milestone at the European policy level was the
launch of HEPAMAP just last month in the European Parliament
in Brussels. We presented the roadmap for liver disease research
in Europe to our policy makers. The intention is to indicate the
research priorities in liver disease from public health through
clinical research to basic research in order to improve the
decision making process and allow more and better funded
liver-oriented projects within the EU framework programs. Even
though this is an important step, EASL recognizes that we have
not yet fulﬁlled our potential regarding advocacy work with the
European governance bodies. Our next step will be the opening
of an EASL EU ofﬁce in Brussels to ensure we have a permanent
representation there for more effective engagement at the EU
level. And the EASL ofﬁce will provide support at the national
level, since health is increasingly being perceived as an individual
member-state issue by the EU; we will foster more active partic-
ipation of EASL members in EU-policy discussion in their home
countries. In addition, we will work on collaborative opinion
building together with other PMOs in areas of relevance for liver
diseases.
EASL will also strengthen its partnerships in science and
education on a global scale. We realized that the highly valued
content presented at the ILC, the EASL Monothematic Confer-
ences and the EASL Schools of Hepatology are not available to
everyone, who would like to access them at the moment. Provid-
ing electronic access for people who cannot attend our meetings
is high on our agenda to ensure we increase EASL’s international
outreach to areas that are more remote or to scientists who have15 vol. 62 j 4–5
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more limited resources to attend these events in person. EASL is
not only providing a full range of electronic education tools
through the LiverTree platform but already has successful educa-
tional activities like the EASL days in Russia and Kazakhstan and
the EASL Schools in China as well as successful scientiﬁc collabo-
rations with international PMOs like APASL, and ALEH, as well as
large national associations with international outreach like
AASLD and others. At the same time, EASL recognizes that in
some of those areas, it is not enough to feature our contents in
English. For that reason we started to provide foreign language
editions of our clinical practice guidelines some time ago in
Chinese, Russian, Spanish and soon also in French and Arabic.
The Journal of Hepatology is running a Chinese edition, and start-
ing this month also a Russian edition of its most relevant manu-
scripts, and we already have iLiver in Spanish with more foreign
language editions to come.
All of this also demands a signiﬁcant transformation of the
organization itself: the EASL ofﬁce, with its dedicated team of
specialists, has already taken over many operational tasks, lead-Journal of Hepatology 2ing to an enormous increase in EASL’s efﬁciency and capacity.
However, much more can be done: EASL leadership has rightly
championed a top-down approach to governance over its ﬁrst
50 years. This has enabled EASL to drive through many radical
ideas. The EASL Governing Board recognizes the beneﬁts but also
the limitations of a small powerful leadership in today’s informa-
tion-rich world and hears the desire of the broader EASL commu-
nity to contribute to the success of its second 50 years and
beyond. This has inspired the creation of several Consorted
Action Groups (CAGs) in the areas of basic research, public health,
young investigators, and Eastern Europe. These CAGs, demon-
strate the hepatology community’s great desire to shape its
own future. As EASL grows further, we will need more of this type
of collaboration and participation. Stay tuned for further
announcements at Vienna and beyond! Only through the contri-
bution of a larger community of highly motivated and dedicated
hepatologists will EASL fulﬁl its vision: to be the ‘Home of Hepa-
tology’, so that everyone involved with liver disease can realize
their full potential to cure and prevent it.015 vol. 62 j 4–5 5
